Standard BioTools (NASDAQ:LAB) Director Buys $338,250.00 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L bought 275,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were bought at an average price of $1.23 per share, for a total transaction of $338,250.00. Following the transaction, the director owned 63,250,000 shares of the company’s stock, valued at approximately $77,797,500. This represents a 0.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Thursday, November 20th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.30 per share, with a total value of $585,000.00.
• On Wednesday, November 19th, Casdin Partners Master Fund, L acquired 350,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.28 per share, for a total transaction of $448,000.00.
• On Monday, November 17th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.22 per share, with a total value of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.24 per share, with a total value of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.20 per share, for a total transaction of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.19 per share, for a total transaction of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.29 per share, with a total value of $129,000.00.

Standard BioTools Stock Performance

Shares of LAB remained flat at $1.28 during mid-day trading on Thursday. 1,905,940 shares of the stock were exchanged, compared to its average volume of 1,658,871. The business has a 50-day simple moving average of $1.28 and a two-hundred day simple moving average of $1.23. The firm has a market cap of $492.24 million, a P/E ratio of -4.00 and a beta of 1.25. Standard BioTools Inc. has a 12-month low of $0.92 and a 12-month high of $2.25.

Hedge Funds Weigh In On Standard BioTools

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Standard BioTools by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock worth $18,603,000 after buying an additional 69,104 shares during the last quarter. XTX Topco Ltd bought a new position in Standard BioTools during the first quarter valued at approximately $171,000. Pacific Capital Partners Ltd purchased a new position in shares of Standard BioTools during the first quarter worth approximately $1,701,000. Rhumbline Advisers raised its stake in shares of Standard BioTools by 11.4% during the first quarter. Rhumbline Advisers now owns 412,761 shares of the company’s stock worth $446,000 after acquiring an additional 42,247 shares in the last quarter. Finally, Long Focus Capital Management LLC bought a new stake in shares of Standard BioTools in the 1st quarter worth approximately $7,236,000. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Cowen downgraded Standard BioTools from a “buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wall Street Zen cut shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Finally, TD Cowen lowered their target price on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.